> top > docs > PubMed:32472461 > annotations

PubMed:32472461 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 0-8 SP_7 denotes COVID-19
T2 124-135 NCBITaxon:11118 denotes coronavirus
T3 150-158 SP_7 denotes COVID-19
T4 197-205 SP_7 denotes COVID-19
T5 251-256 CHEBI:23888 denotes Drugs
T6 251-256 CHEBI:23888 denotes Drugs
T7 411-416 CHEBI:67079 denotes anti-
T8 411-416 CHEBI:67079 denotes anti-
T9 426-431 CHEBI:23888 denotes drugs
T10 426-431 CHEBI:23888 denotes drugs
T11 489-492 PR:000001393 denotes IL6
T12 494-499 PR:000000134 denotes TNF α
T13 516-524 SP_7 denotes COVID-19
T14 646-654 SP_7 denotes COVID-19
T15 885-899 CHEBI:67079 denotes anti-rheumatic
T16 885-899 CHEBI:67079 denotes anti-rheumatic
T17 900-905 CHEBI:35472 denotes drugs
T18 900-905 CHEBI:35472 denotes drugs
T19 921-929 SP_7 denotes COVID-19

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-79 Sentence denotes COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.
T2 80-196 Sentence denotes Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem.
T3 197-250 Sentence denotes COVID-19 appeared in Wuhan (Hubei province) in China.
T4 251-384 Sentence denotes Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied.
T5 385-544 Sentence denotes The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF α) in the body by COVID-19 in its severe form.
T6 545-860 Sentence denotes In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted.
T7 861-940 Sentence denotes The authors also review anti-rheumatic drugs while studying COVID-19 treatment.
T1 0-79 Sentence denotes COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.
T2 80-196 Sentence denotes Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem.
T3 197-250 Sentence denotes COVID-19 appeared in Wuhan (Hubei province) in China.
T4 251-384 Sentence denotes Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied.
T5 385-544 Sentence denotes The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF α) in the body by COVID-19 in its severe form.
T6 545-860 Sentence denotes In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted.
T7 861-940 Sentence denotes The authors also review anti-rheumatic drugs while studying COVID-19 treatment.